Investigating the efficacy of integrating video-directly observed therapy (VDOT) in the treatment of tuberculosis (TB): A statewide analysis from Florida

IF 1.9 Q3 INFECTIOUS DISEASES
Aneesha Raj , Nabiha S. Khakoo , Alex A. Ashkin , Mary T. Green , Rene R. Tresgallo
{"title":"Investigating the efficacy of integrating video-directly observed therapy (VDOT) in the treatment of tuberculosis (TB): A statewide analysis from Florida","authors":"Aneesha Raj ,&nbsp;Nabiha S. Khakoo ,&nbsp;Alex A. Ashkin ,&nbsp;Mary T. Green ,&nbsp;Rene R. Tresgallo","doi":"10.1016/j.jctube.2024.100471","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>To determine if integrating VDOT into TB therapy demonstrated non-inferiority to direct observation, and if VDOT utilization increased across Florida after the onset of Covid-19.</p></div><div><h3>Methods</h3><p>A statewide programmatic review was conducted of all patients in Florida who initiated tuberculosis treatment between January 2018 – December 2018 and January 2020 – December 2021, as documented by the Florida Department of Health.</p></div><div><h3>Results</h3><p>1361 patients received treatment within the analysis timeframe. Therapy completion was 97.2% in those utilizing VDOT compared to 92.3% utilizing only DOT (<em>p=&lt;.001</em>). Average duration of therapy was 220.5 days in the DOT-only cohort compared to 211.1 days with VDOT integration (<em>p=.027</em>). A 176.35% increase in VDOT utilization was seen across Florida during Covid-19.</p></div><div><h3>Conclusions</h3><p>This is the first and largest state-wide study evaluating the efficacy of integrating VDOT into TB therapy, finding statistically significant improvements in completion and duration of therapy. Despite increased VDOT utilization since the onset of Covid-19, we suspect that multiple barriers may be hindering further integration. VDOT should be recommended as a cost effective, non-inferior alternative to DOT in monitoring the treatment of tuberculosis.</p></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"37 ","pages":"Article 100471"},"PeriodicalIF":1.9000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405579424000585/pdfft?md5=53a81a011b7f7bc2a5244b626b2d383d&pid=1-s2.0-S2405579424000585-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405579424000585","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

To determine if integrating VDOT into TB therapy demonstrated non-inferiority to direct observation, and if VDOT utilization increased across Florida after the onset of Covid-19.

Methods

A statewide programmatic review was conducted of all patients in Florida who initiated tuberculosis treatment between January 2018 – December 2018 and January 2020 – December 2021, as documented by the Florida Department of Health.

Results

1361 patients received treatment within the analysis timeframe. Therapy completion was 97.2% in those utilizing VDOT compared to 92.3% utilizing only DOT (p=<.001). Average duration of therapy was 220.5 days in the DOT-only cohort compared to 211.1 days with VDOT integration (p=.027). A 176.35% increase in VDOT utilization was seen across Florida during Covid-19.

Conclusions

This is the first and largest state-wide study evaluating the efficacy of integrating VDOT into TB therapy, finding statistically significant improvements in completion and duration of therapy. Despite increased VDOT utilization since the onset of Covid-19, we suspect that multiple barriers may be hindering further integration. VDOT should be recommended as a cost effective, non-inferior alternative to DOT in monitoring the treatment of tuberculosis.

研究视频直接观察疗法(VDOT)在结核病(TB)治疗中的综合疗效:佛罗里达州的全州分析
目标确定将 VDOT 纳入结核病治疗是否显示出非劣于直接观察,以及在 Covid-19 开始后,佛罗里达州的 VDOT 利用率是否有所提高。方法对佛罗里达州卫生部记录的 2018 年 1 月至 2018 年 12 月和 2020 年 1 月至 2021 年 12 月期间开始接受结核病治疗的所有患者进行全州范围的项目审查。使用 VDOT 的患者治疗完成率为 97.2%,而仅使用 DOT 的患者治疗完成率为 92.3%(p=<.001)。仅使用 DOT 的患者平均治疗时间为 220.5 天,而使用 VDOT 的患者平均治疗时间为 211.1 天(p=.027)。在 Covid-19 期间,整个佛罗里达州的 VDOT 使用率增加了 176.35%。结论这是第一项评估将 VDOT 纳入结核病治疗的疗效的全州范围内最大规模的研究,发现在完成治疗和治疗持续时间方面有统计学意义的显著改善。尽管自 Covid-19 开始以来,VDOT 的使用率有所提高,但我们怀疑可能有多种障碍阻碍了进一步的整合。在监测结核病治疗方面,VDOT 应被推荐为一种具有成本效益且不劣于 DOT 的替代方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Medicine-Pulmonary and Respiratory Medicine
CiteScore
4.00
自引率
5.00%
发文量
44
审稿时长
30 weeks
期刊介绍: Journal of Clinical Tuberculosis and Mycobacterial Diseases aims to provide a forum for clinically relevant articles on all aspects of tuberculosis and other mycobacterial infections, including (but not limited to) epidemiology, clinical investigation, transmission, diagnosis, treatment, drug-resistance and public policy, and encourages the submission of clinical studies, thematic reviews and case reports. Journal of Clinical Tuberculosis and Mycobacterial Diseases is an Open Access publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信